Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Open access

Abstract

Aims/hypothesis: The aim of this study was to assess the dose–response effects of the subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide (BI 456906) on HbA 1c levels and bodyweight reduction. Methods: This Phase II, multicentre, randomised, double-blind, parallel-group, placebo-controlled study, conducted in clinical research centres, assessed survodutide in participants aged 18–75 years with type 2 diabetes, an HbA 1c level of 53–86 mmol/mol (7.0–10.0%) and a BMI of 25–50 kg/m 2 on a background of metformin therapy. Participants were randomised via interactive response technology to receive survodutide (up to 0.3, 0.9, 1.8 or 2.7 mg once weekly [qw; dose group (DG) 1–4, respectively] or 1.2 or 1.8 mg twice weekly [DG 5 and 6, respectively]), placebo or semaglutide (up to 1.0 mg qw). Participants and all those involved in the trial conduct/analysis were blinded; the semaglutide arm was open-label. The primary endpoint was absolute change from baseline in HbA 1c after 16 weeks’ treatment. The key secondary endpoint was relative change from baseline in bodyweight after 16 weeks’ treatment. Results: A total of 413 participants were randomised (DG1, n =50; DG2, n =50; DG3, n =52; DG4, n =50; DG5, n =51; DG6, n =50; semaglutide, n =50; placebo, n =60). The full analysis set comprised 411 treated participants (DG6, n =49; placebo, n =59). Adjusted mean (95% CI) HbA 1c decreased from baseline (mean ± SD 64.7±9.2 mmol/mol [8.07±0.84%] after 16 weeks’ treatment: DG1 ( n =41), −9.92 mmol/mol (−12.27, −7.56; −0.91% [−1.12, −0.69]); DG2 ( n =46), −15.95 mmol/mol (−18.27, −13.63; −1.46% [−1.67, −1.25]); DG3 ( n =36), −18.72 mmol/mol (−21.15, −16.29; −1.71% [−1.94, −1.49]); DG4 ( n =33), −17.01 mmol/mol (−19.59, −14.43; −1.56% [−1.79, −1.32]); DG5 ( n =44), −17.84 mmol/mol (−20.18, −15.51; −1.63% [−1.85, −1.42]); DG6 ( n =36), −18.38 mmol/mol (−20.90, −15.87; −1.68% [−1.91, −1.45]). The mean reduction in HbA 1c was similar with low-dose survodutide (DG2: −15.95 mmol/mol [−1.46%]; n =46) and semaglutide (−16.07 mmol/mol [−1.47%]; n =45). Mean (95% CI) bodyweight decreased dose-dependently up to −8.7% (−10.1, −7.3; DG6, n =37); survodutide ≥1.8 mg qw produced greater bodyweight reductions than semaglutide (−5.3% [−6.6, −4.1]; n =45). Adverse events (AEs) were reported for 77.8% of survodutide-treated participants (mainly gastrointestinal), 52.5% receiving placebo and 52.0% receiving semaglutide. Conclusions/interpretation: Survodutide reduced HbA 1c levels and bodyweight after 16 weeks’ treatment in participants with type 2 diabetes. Dose-related gastrointestinal AEs could be mitigated with slower dose escalations. Trial registration: ClinicalTrials.gov NCT04153929 and EudraCT 2019-002390-60. Funding: Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany. Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-023-06053-9

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 MMRM estimates for the absolute change in HbA1c from baseline to EoT. aSemaglutide arm was open label
Fig. 1 MMRM estimates for the absolute change in HbA1c from baseline to EoT. aSemaglutide arm was open labelCC BY · PubMed Central
Fig. 2 MMRM estimates for the relative change in bodyweight from baseline to EoT. aSemaglutide arm was open label
Fig. 2 MMRM estimates for the relative change in bodyweight from baseline to EoT. aSemaglutide arm was open labelCC BY · PubMed Central
Fig. 3 Change from baseline in 7-point SMBG. Blood glucose measurements were collected before each meal (assuming three meals a day), approximately 2 h after each meal and at bedtime on a single day during screening (baseline) and a single day between the last dose of study drug and EoT (week 16). Mean overall time points represent the mean per participant per visit of the seven blood glucose measurements at baseline and week 16. Data are presented per DG. The centre line denotes the median value, with the symbols within the boxes denoting the mean. The box boundaries mark the upper and lower quartile of the dataset. The whiskers indicate the variability of the data; whiskers are drawn to the nearest value within 1.5× the IQR of the upper and lower quartiles. Any observations outside of these values are plotted with symbols. aSemaglutide arm was open label
Fig. 3 Change from baseline in 7-point SMBG. Blood glucose measurements were collected before each meal (assuming three meals a day), approximately 2 h after each meal and at bedtime on a single day during screening (baseline) and a single day between the last dose of study drug and EoT (week 16). Mean overall time points represent the mean per participant per visit of the seven blood glucose measurements at baseline and week 16. Data are presented per DG. The centre line denotes the median value, with the symbols within the boxes denoting the mean. The box boundaries mark the upper and lower quartile of the dataset. The whiskers indicate the variability of the data; whiskers are drawn to the nearest value within 1.5× the IQR of the upper and lower quartiles. Any observations outside of these values are plotted with symbols. aSemaglutide arm was open labelCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 157

Metadata

Authors
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M.
Affiliations
  • Helmholtz Munich (DE)
  • Boehringer Ingelheim (United States) (US)
  • Boehringer Ingelheim (Germany) (DE)
Corresponding author
  • Blüher, Matthias
  • Hennige, Anita M.
Venue
Diabetologia
Published
2023-12-14
Volume
67
Issue
3
Pages
470-482
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4389739323
Cited by
138
References
28
Citations by year
2026: 50 · 2025: 42 · 2024: 46
FWCI
28.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Qucosa (Saxon State and University Library Dresden) (publishedVersion, other-oa)
  • PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
Funders
  • Boehringer Ingelheim
  • Universität Leipzig
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
survodutide, type 2 diabetes, HbA1c, dose-response relationship, semaglutide, metformin, weight loss, glycemic control, GLP-1 receptor agonists, glucagon receptor agonist
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Glucagon, Humans, Hypoglycemic Agents, Peptides, Treatment Outcome, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. https://app.cochat.ai/papers/10.1007/s00125-023-06053-9
The paper
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M. (2024). Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. https://doi.org/10.1007/s00125-023-06053-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.